Skip to main content
Delfa

← Trials/Trial dossier/NCT00414622

CompletedPhase 2

GTS21-201 for Alzheimer Disease:GTS-21 Administered Daily for 28 Days to Participants With Probable Alzheimer's Disease

A Double Blind, Placebo-Controlled Randomized Study to Compare the Safety and Tolerability of GTS-21 (25 Mg TID, 50 Mg TID, 75 Mg TID and 150 Mg TID) When Administered Daily for 28 Days to Participants With Probable Alzheimer's Disease

Lead sponsor

CoMentis

Asset

DMXB-A

Listed sites

1

Recruiting sites

-

Enrollment

60

Study population

Alzheimer’s disease

Key I/E criterion

•Age 50-80

Primary endpoint

•CDR

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study IDGTS21-201
NCT IDNCT00414622

Timeline

Milestones

Study start2006-11 (month precision)
Study first posted2006-12-21estimated
Study completion2007-04actual (month precision)
Last update posted2007-04-19estimated

Assets

Drug assets

DMXB-A

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age50 Years
Maximum age80 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•probable Alzheimer

Exclusion criteria

•others

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Global cognition
1
Other (unclassified)
1

Global cognition

1 endpoint
Secondary/protocol endpoint

ADAS-cog

ADAS-Cog

descriptive

Other (unclassified)

1 endpoint
Primary/protocol endpoint/low confidence

CDR

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 21, 2026
Endpoint classificationDelfa ADRD endpoint taxonomy
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.